Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
10.55
+0.59 (5.92%)
At close: Nov 28, 2025, 4:00 PM EST
10.38
-0.17 (-1.61%)
After-hours: Nov 28, 2025, 4:00 PM EST
Kazia Therapeutics Revenue
In the fiscal year ending June 30, 2025, Kazia Therapeutics had annual revenue of 1.83M AUD, down -26.28%. Kazia Therapeutics had revenue of 1.81M in the half year ending June 30, 2025, with 180,571.00% growth.
Revenue (ttm)
1.83M AUD
Revenue Growth
-26.28%
P/S Ratio
9.10
Revenue / Employee
304,833 AUD
Employees
6
Market Cap
19.36M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.83M | -652.00K | -26.28% |
| Jun 30, 2024 | 2.48M | 2.48M | 248,000.00% |
| Jun 30, 2023 | 1,000.00 | -9.00K | -90.00% |
| Jun 30, 2022 | 10.00K | -15.17M | -99.93% |
| Jun 30, 2021 | 15.18M | 14.19M | 1,436.54% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KZIA News
- 10 days ago - Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy - PRNewsWire
- 4 weeks ago - Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner - PRNewsWire
- 7 weeks ago - Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program - PRNewsWire
- 2 months ago - Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen - PRNewsWire
- 2 months ago - Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG - PRNewsWire
- 2 months ago - Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy - PRNewsWire
- 4 months ago - Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market - PRNewsWire
- 5 months ago - Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial - PRNewsWire